Simple, Rapid and Inexpensive Quantitative Fluorescent PCR Method for Detection of Microdeletion and Microduplication Syndromes

Martin Stofanko¹, Higgor Gonçalves-Dornelas¹, Pricila Silva Cunha², Heloísa B. Pena¹, Angela M. Vianna-Morgante³, Sérgio Danilo Junho Pena¹,²*

¹GENE - Núcleo de Genética Médica, Belo Horizonte, Minas Gerais, Brazil, ²Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ³Departamento de Genética e Biologia Evolutiva, Instituto de Biociências Universidade de São Paulo, São Paulo, São Paulo, Brazil

Abstract

Because of economic limitations, the cost-effective diagnosis of patients affected with rare microdeletion or microduplication syndromes is a challenge in developing countries. Here we report a sensitive, rapid, and affordable detection method that we have called Microdeletion/Microduplication Quantitative Fluorescent PCR (MQF-PCR). Our procedure is based on the finding of genomic regions with high homology to segments of the critical microdeletion/microduplication region. PCR amplification of both using the same primer pair, establishes competitive kinetics and relative quantification of amplicons, as happens in microsatellite-based Quantitative Fluorescence PCR. We used patients with two common microdeletion syndromes, the Williams-Beuren syndrome (7q11.23 microdeletion) and the 22q11.2 microdeletion syndromes and discovered that MQF-PCR could detect both with 100% sensitivity and 100% specificity. Additionally, we demonstrated that the same principle could be reliably used for detection of microduplication syndromes, by using patients with the Lubs (MECP2 duplication) syndrome and the 17q11.2 microduplication involving the NF1 gene. We propose that MQF-PCR is a useful procedure for laboratory confirmation of the clinical diagnosis of microdeletion/microduplication syndromes, ideally suited for use in developing countries, but having general applicability as well.

Introduction

Microdeletion and microduplication syndromes comprise a large group of human diseases that arise from imbalance in the transcription of genes due to partial loss or gain of genetic material of, typically, less than 5 Mb [1]. Symptoms range widely, but frequently encompass mental retardation, autism, physical dysmorphism and/or organ malformations.

Many microdeletion or microduplication syndromes can be diagnosed on the basis of phenotype alone, but molecular confirmation is essential for correct and reliable clinical and genetic prognoses. For that, a variety of techniques can be used, ranging from microscopic methods, such as Fluorescence in situ Hybridization (FISH), to molecular methods involving PCR and genome-wide microarrays [2,3].

In a broad sense, laboratory diagnostic strategies can be classified as non-targeted or targeted. The most important non-targeted approaches are Array Comparative Genomic Hybridization (aCGH) and Single Nucleotide Polymorphism (SNP) arrays.

The former has become the method of choice for diagnosis of microdeletions and microduplications in the US and Europe, while the latter provide a higher sensitivity to detect mosaic aneuploidies and is also capable of simultaneously diagnosing uniparental disomies and consanguinity [4–6]. Unfortunately, the very high cost of these analyses makes these methods inappropriate for the public healthcare system in developing countries.

Well-known targeted diagnostic approaches include FISH, Real-Time PCR and Multiplex Ligation-dependent Probe Amplification (MLPA) [2,3,7]. FISH is a complex and time-consuming method that needs special equipment, has limited resolution and is not appropriate for diagnosis of some microduplications [8,9]. Quantitative Real-Time PCR discriminates between normal and affected individuals by differential amplification of target sequence due to different amounts of starting template DNA between control and deleted region. It offers fast turnaround time and technical feasibility, but it has limited multiplexing capabilities and suffers from reproducibility issues [10,11]. In MLPA, a combination of probe hybridization and
diagnosis of microdeletion/microduplication syndromes easily accessible for low-budget laboratories in developing countries.

All diagnostic methods based on quantitative comparison between amplification of target and control fragments using two different primer sets share a common constraint, the inherently unreliable amplification of distinct PCR fragments. This happens because PCR amplification is a complex exponential phenomenon and small differences in initial conditions may have a profound impact on the amounts of product obtained. To overcome this limitation, in 1991, Mutter and Pomponio reported on a simple PCR-based molecular technique that reliably permitted the diagnosis of dosage alterations of the human X and Y chromosomes [14]. They made use of differences in the sequences of the ZFX gene on the Y chromosome and its homolog ZFY on the X chromosome to design a single primer pair that led to the amplification of both genes. They showed that under these internal genomic competitive conditions it was possible to diagnose reliably individuals with 47,XXY or 47,XYY since the relative amounts of ZFX and ZFY products (differentiated by restriction analysis) were in 2:1 and 1:2 ratios, respectively, in contrast with a 1:1 ratio for normal controls. This internally controlled means of establishing gene dosage in diagnosing human trisomy was further explored by Mansfield [15] who first utilized human polymorphic microsatellites in quantitative fluorescent PCR (QF-PCR), a method that has become widely used for the prenatal diagnosis of several human aneuploidies [16], and later by Lee et al. [17] who pioneered the use of simultaneous amplification of homologous genes in a method that they called HGQ-PCR. Both methods could reliably quantify amplicons of different sizes and thus determine chromosome dosage. Later, the attractive rationale of the HGQ-PCR method was explored, with technical variations, by Deutsch et al. [18] and Armour et al. [19] in detection of microsatellites in quantitative fluorescent PCR (QF-PCR), a method that can reliably quantify amplicons of different sizes and thus determine chromosome dosage. Later, the attractive rationale of the HGQ-PCR method was explored, with technical variations, by Deutsch et al. [18] and Armour et al. [19] in detection of aneuploidy and genes with high copy number variation, respectively.

We show that the principle of the HGQ-PCR method of Lee et al. [17] can be used as a simple, rapid, DNA quality independent and internally controlled PCR-based detection test for sub-microscopic genome rearrangements that we have called Microdeletion/Microduplication Quantitative Fluorescent PCR (MQF-PCR). We used two very common microdeletion syndromes, the Williams-Beuren syndrome (WBS); (OMIM #194050) and the 22q11.2 microdeletion syndromes [Velocardiofacial syndrome (VCF); (OMIM #192430) and Di George syndrome (OMIM #188400)] to demonstrate the reliability and cost-efficiency of MQF-PCR. Additionally, we demonstrate that the same principle can be reliably used for detection of two microduplications syndromes, by using as examples the Labs syndrome, involving the MECP2 gene on Xq28 chromosome (OMIM #300260) and the 17q11.2 microduplication, involving the NEUROFIBROMIN 1 (NF1) gene (OMIM #613113). We propose that MQF-PCR is a very useful procedure for laboratory confirmation of the clinical diagnosis of microdeletion/microduplication syndromes.

**Materials and Methods**

**Ethics Statement**

For the purpose of the assay development we used human subjects previously diagnosed with known microdeletion syndromes at GENE - Núcleo de Genética Médica, Belo Horizonte, MG, Brazil. The participants did not provide written or verbal consent and no other formal documented measures were taken. Since no new samples were needed, we chose to avoid the need to contact patients by using anonymization. Thus, DNA samples previously used for diagnosis and stored in our clinic were anonymized and used in testing the new diagnostic procedure. Since the new tests uniformly confirmed the previous diagnoses, they had value by adding reliability to them. This study was approved by the Ethics Committee of Santa Casa de Misericórdia in Belo Horizonte.

**Patients**

Genomic DNA from normal male and female control individuals, and individuals previously diagnosed with specific microdeletion or microduplication syndromes (Table 1) was isolated from buccal swabs using a salting-out protocol [20].

We studied initially 14 patients with the Williams-Beuren syndrome who had confirmation of their clinical diagnoses by studies of loss of heterozygosity of four microsatellites located in

| Syndrome | Patient | Z (PZ)-statistics score [34] |
|----------|---------|-----------------------------|
| Williams-Beuren | 194 | -4.57 |
| | 385 | -5.04 |
| | 603 | -5.33 |
| | 604 | -5.29 |
| | 3105 | -5.10 |
| | 4183 | -4.68 |
| | 4282 | -5.13 |
| | 7350 | -5.11 |
| | 8184 | -5.47 |
| | 9234 | -5.38 |
| | 10498 | -4.76 |
| | 11275 | -4.78 |
| | 11469 | -5.05 |
| | 12681 | -5.55 |
| Velocardiofacial | 8432 | (-2.87) |
| | 8441 | (-3.93) |
| | 9146 | (-1.37) |
| | 10097 | (-2.45) |
| | 10127 | (-1.93) |
| | 10332 | (-2.17) |
| | 10460 | (-3.03) |
| | 11153 | (-3.03) |
| Labs (MECP2 duplication) | 15982A [27,29] | 6.56 |
| | 15982B [27,29] | 4.12 |
| | 17863A [28] | 9.40 |
| | 17863B [28] | 7.65 |
| 17q11.2 microduplication [30] | NF1dup1 | 11.51 |
| | NF1dup2 | 11.27 |
| | NF1dup3 | 10.89 |

doi:10.1371/journal.pone.0061328.t001
the critical region of the 7q11.23 microdeletion syndrome (a CCTT tetranucleotide polymorphism in the ELN gene [21] and three CA repeat polymorphisms, in the ELN gene [22], in the LIMK1 gene [23] and in D7S1670 [24], respectively). The diagnosis of these patients was further confirmed by Real-Time PCR using a 122 bp amplicon for the ELN gene chr7:7,547,477–7,547,486 and a 149 bp amplicon in the LIMK1 gene (chr7:7,530,004–7,530,152). One patient had the diagnosis confirmed by aCGH.

We studied next eight patients clinically diagnosed as having the VCF syndrome. Laboratory confirmation of the clinical diagnoses were obtained by loss of heterozygosity studies of three microsatellites located in the critical region of the 22q11.2 microdeletion syndrome (the three CA repeat polymorphisms D22S264 [25] and D22S941 and D22S944 [26], respectively). Further molecular confirmation was obtained by Real-Time PCR using four different amplicons as described by Weksberg et al. [10]: a 101 bp amplicon for the CAT4 gene (chr22:21,384,130–21,384,230), 101 bp amplicon in the PRODH gene (chr22:18,918,663–18,918,763), a 101 bp amplicon in the PIK3CA gene (chr22:21,105,251–21,105,351), and a 100 bp amplicon in the COMT gene (chr22:19,956,086–19,956,185).

DNA samples from four patients (two pairs of affected brothers) with Lubs syndrome (microduplication of MEGC2) were used [27–29]. DNAs from three patients with 17q11.2 microduplication, involving the Neurofibromatosis type 1 deletion syndrome critical region (OMIM #162900) diagnosed by aCGH and FISH, were a kind gift of Dr. Lisa G. Shaffer and Dr. Jill Mokry from the Signature Genomics Laboratories, Spokane, WA, USA [30]. To account for individual copy number variations, a reference DNA sample was created by pooling DNA from 100 male normal Brazilian individuals and used statistically to normalize results.

MQF-PCR Assay Development

Minimal critical regions of each of the microdeletion syndromes (Table 1, GRCh37 human genome assembly) were used as queries for BLASTN (http://blast.ncbi.nlm.nih.gov) to identify regions with high sequence similarity that varied by 1–10 bp in length. In order to obtain maximum number of unique homologous regions, query sequences were split into 100–200 kb portions. Candidate pairs of highly homologous sequences were screened for 15–20 bp nucleotide stretches of absolute or highly conserved match representing potential detection primers. These were used as input for UCSC In-Silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start) to confirm amplification of the two potentially diagnostic sequences. Both coding and non-coding sequences were considered. Candidate pairs of gene regions and their corresponding homologous sequences were then screened for presence of known copy number variations in Database of Genomic Variants and SNPed (http://projects.tcag.ca/variation; http://www.scanb.org). PCR primers (Table 2) were evaluated in Primer3 (http://frodo.wi.mit.edu) for optimal GC content, annealing temperature, and mispriming. Forward and reverse primers were tailed at the 5’ end using the M13-40 sequence to allow fluorescent labeling of amplicons with a NED-labeled primer, targeting an exon of LIMK1 [10] (Figure 1A) contains several genes which, when in single copy,
contribute to the phenotype of the syndrome [40]. We screened as a candidate the *LIMK1* gene, which is deleted in all WBS patients including atypical cases [41]. One segment (chr7:73,536,635–73,536,831) showed homology to a region on chromosome 18p11.32 (chr18:675,837–676,031). Both *LIMK1* and its homologous region on chromosome 18 could be amplified using the LIMK1-MQF primer pair (Table 2). On PCR, two amplicons were observed, one with a size of 214 bp (originating from the chromosome 18 homologue) and another, 4 bp longer, originating from the WBS critical region. Since WBS deletion patients were hemizygous, having only half of the starting amount of template DNA in comparison with the control region in chromosome 18, we expected a corresponding 50% reduction in PCR amplification compared with a normal individual. Figure 2A–B shows an electropherogram depicting change of peak area between a region on chromosome 7q11.23 (shown in black) and its control chromosome (white) in normal (Figure 2A) and the patient 11469 (Figure 2B). Indeed, the peak area ratio between the control and the WBS patient is reduced by about 50%. We then evaluated the detection performance of the MQF primers for the Williams-Beuren microdeletion syndrome using ROC curve analysis (Figure 2E). Amplification of these two regions using the VCF-MQF primer that we designed (Table 2) resulted in two amplicons with size 99 bp (originating in chromosome 22) and 104 bp (originating in chromosome 3), differing by 5 bp in size. As an example, the change of peak area ratios between a region on chromosome 22q11.2 (shown in black) and its control chromosome (white) in a VCF patient and a normal individual is shown in Figure 2C–D. Similarly to the case with the Williams-Beuren microdeletion, the peak area ratio between the control (Figure 2C) and the VCF patient (Figure 2D) is reduced by about 50%. The detection performance of the primers for the 22q11.2 microdeletion was evaluated using ROC curve analysis. The normalized ratios in controls did not conform to Gaussian distribution, and thus the pseudo-Z score was calculated [34]. Using the PZ-score values the diagnostic primer achieved 100% sensitivity and 100% specificity (Figure 2F). The PZ-scores for all diagnosed patients are summarized in Table 1. The probabilities of a true positive result (positive predictive value) were estimated at 100% (95% confidence interval = 60–100%), a false positive result at 0% (95% confidence interval = 0–40%), a true negative result (negative predictive value) at 100% (95% confidence interval = 92–100%), and a false negative result at 0% (95% confidence interval = 0–8%). These results further confirm that MQF-PCR presents a reliable method for the detection of human microdeletion syndromes.

### Studies on the Velocardiofacial Syndrome (OMIM #192430)

Having had excellent results with the Williams-Beuren syndrome, we then moved on to additionally study the very common microdeletion syndrome, Velocardiofacial syndrome, that results from hemizygosity for 22q11 [42]. We studied eight patients clinically diagnosed as having the VCF syndrome. The VCF critical region (Figure 2B) at position 22q11.12 is delimited by blocks of low copy repeats (LCRs). The vast majority of observed typical deletions share a common deleted region flanked by two LCRs most proximal to centromere (black boxes in Figure 1B), referred to by Shaikh et al. [42] as Block A and Block B. Within this region, a candidate sequence (chr22:19,618,131–19,618,209) about 120 kb upstream of *TBX1* showed significant similarity to a homologous region at 3p11.1 (chr3:38,205,817–88,205,900). Amplification of these two regions using the VCF-MQF primer that we designed (Table 2) resulted in two amplicons with size 99 bp (originating in chromosome 22) and 104 bp (originating in chromosome 3), differing by 5 bp in size. As an example, the change of peak area ratios between a region on chromosome 22q11.2 (shown in black) and its control chromosome (white) in a VCF patient and a normal individual is shown in Figure 2C–D. Similarly to the case with the Williams-Beuren microdeletion, the peak area ratio between the control (Figure 2C) and the VCF patient (Figure 2D) is reduced by about 50%. The detection performance of the primers for the 22q11.2 microdeletion was evaluated using ROC curve analysis. The normalized ratios in controls did not conform to Gaussian distribution, and thus the pseudo-Z score was calculated [34]. Using the PZ-score values the diagnostic primer achieved 100% sensitivity and 100% specificity (Figure 2F). The PZ-scores for all diagnosed patients are summarized in Table 1. The probabilities of a true positive result (positive predictive value) were estimated at 100% (95% confidence interval = 60–100%), a false positive result at 0% (95% confidence interval = 0–40%), a true negative result (negative predictive value) at 100% (95% confidence interval = 92–100%), and a false negative result at 0% (95% confidence interval = 0–8%). These results further confirm that MQF-PCR presents a reliable method for the detection of human microdeletion syndromes.

### Studies on Microduplication Syndromes

To test the efficiency of MQF-PCR in the detection of microduplication events, we studied the X-linked microduplication syndrome at Xq28 (Lubs syndrome; OMIM #300260) and an autosomal duplication involving the gene *NF1*. For the former, we scanned the MECP2 duplication critical region [43] and identified a sequence (chrX:153,276,119–153,276,295) that shared high homology with a sequence on chromosome 5p13.3 (chr5:32,649,017–32,649,192). PCR amplification using the same primer pair (Table 2) yielded two fragments that differed by 1 bp in size. Two patients, previously described [29–31] were studied, and one affected brother of each was also analyzed. Figure 3A–B shows an electropherogram illustrating changes in peak area ratio between control (Figure 3A) and a patient known to have the MECP2 microduplication (Figure 3B). The area of the peak corresponding to chromosome Xp28 (black) had approximately doubled compared to the control peak area (white). Similar results were obtained for the other 3 patients known to have the MECP2

---

**Table 2. MQF-PCR primers used in detection of microdeletion and microduplication syndromes.**

| Syndrome                      | Primer name | Sequences (5′-3′) | Fragment sizes | Genomic locations (GRCh37) |
|-------------------------------|-------------|-------------------|----------------|---------------------------|
| Williams-Beuren               | WBS-MQF-F   | TGGAGGGGACCTTTGTCAC<sup>a</sup> | chr7: 218 bp | chr7: 73,536,635–73,536,831 |
|                               | WBS-MQF-R   | TTATTGGTCCGCTCCTGGG<sup>b</sup> | chr18: 214 bp | chr18: 675,837–676,031   |
| Velocardiofacial              | VCF-MQF-F   | GATAACTGGGTTCTACGAC<sup>c</sup> | chr22: 99 bp | chr22: 19,618,131–19,618,209 |
|                               | VCF-MQF-R   | TTATTGGTCCGCTCCTGGG<sup>c</sup> | chr3: 104 bp | chr3: 88,205,817–88,205,900 |
| Lubs (MECP2 duplication)      | LUBS-MQF-F  | TGAAACCTGGTCAGTCTGT<sup>d</sup> | chrX: 197 bp | chrX: 153,276,119–153,276,295 |
|                               | LUBS-MQF-R  | GCACGTAGTCTGGAGACGAG<sup>d</sup> | chr5: 196 bp | chr5: 32,649,017–32,649,192 |
| 17q11.2 microduplication      | NF1-MQF-F   | TTATGGTCCGCTCCTGGG<sup>c</sup> | chr7: 159 bp | chr7: 29,468,898–29,469,033 |
|                               | NF1-MQF-R   | GGCCTATAGACCATGAG<sup>b</sup> | chr13: 153 bp | chr13: 19,673,801–19,673,931 |

<sup>a</sup>Universal M13-40 extension (5′-GTTTTCACGTCGTCGAG-3′) was added to the 5′ end of the primer to allow for cost-efficient fluorescent labelling of amplicons [31].

<sup>b</sup>A P5- tail extension (5′-GTTTTCACGTCGTCGAG-3′) was added to the 5′ end of the primer to promote full adenylation of the 3′ end of the forward strand [32].

doi:10.1371/journal.pone.0061328.0002
microduplication syndrome. The detection performance of the primers for the Lubs syndrome was evaluated using ROC curve analysis. Using the Z-score values [34] summarized in Table 1, the diagnostic primer achieved 100% sensitivity and 100% specificity (Figure 3E). The probabilities of a true positive result (positive predictive value) were estimated at 100% (95% confidence interval = 40–100%), a false positive result at 0% (95% confidence interval = 0–60%), a true negative result (negative predictive value) at 100% (95% confidence interval = 91–100%), and a false negative result at 0% (95% confidence interval = 0–9%).

For the autosomal duplication involving the gene \( \text{NF1} \) we designed a diagnostic primer in the critical region at 17q11.2 (chr17:29,468,898–29,469,033) that shared high homology with a sequence on chromosome 13q12.11 (chr13:19,673,801–19,673,931). PCR amplification using the same primer pair (Table 2) yielded two fragments that differed by 6 bp in size. We studied three patients previously diagnosed by FISH and aCGH with microduplication of \( \text{NF1} \) (OMIM #613113) [30]. Figure 3C–D shows an electropherogram illustrating changes in peak area ratio between control (Figure 3C) and a patient known to have the 17q11.2 microduplication (Figure 3D). The area of the peak corresponding to chromosome 17q11.2 (black) had increased by about 30% compared to the control peak area (white). We observed similar results with the other two patients. The detection performance of the primers for the 17q11.2 microduplication was evaluated using ROC curve analysis. Using the Z-score values [34] summarized in Table 1, the diagnostic primer achieved 100% sensitivity and 100% specificity (Figure 3F). The probabilities of a true positive result (positive predictive value) were estimated at 100% (95% confidence interval = 31–100%), a false positive result at 0% (95% confidence interval = 0–60%), a true negative result (negative predictive value) at 100% (95% confidence interval = 91–100%), and a false negative result at 0% (95% confidence interval = 0–9%).

Figure 1. Schematic overview of MQF-PCR primer selection for Williams-Beuren and Velocardiofacial syndromes critical regions (not drawn to scale). A) Williams-Beuren critical region at 7q11.23 contains centromeric (white arrow), middle (grey arrow), and telomeric (black arrow) blocks of low copy repeats. The minimal critical region in this study represents the region that is flanked by the inner block of low copy repeats. Sequence similarity search identified a region that can be amplified using the LIMK1-MQF primers (bold) and has significant similarity to homologous region at 18p11.32. B) Multiple sequence alignment of the LIMK1-MQF region with its homologous region on chromosome 18. A deletion of 2 bp (dashed box) differentiates the two fragments amplified using the same primer pair. C) Velocardiofacial critical region at 22q11.2 is delimited by 4 blocks of low copy repeats. The minimal critical region in this study represents the region that is flanked by two blocks of low copy repeats most proximal to the centromere (black boxes). Sequence similarity search identified a region within the critical region that can be amplified using the VCF-MQF primers (bold) with significant similarity to a homologous region at 3p11.1. D) Multiple sequence alignment of the VCF-MQF region with its homologous region on chromosome 3. A deletion of 5 bp (dashed box) differentiates the two fragments amplified using the same primer pair. Microsatellite markers (italicized) and Real-Time PCR primers used in molecular diagnosis of patients are shown in both panels.

doi:10.1371/journal.pone.0061328.g001
at 0% (95% confidence interval = 0–69%), a true negative result (negative predictive value) at 100% (95% confidence interval = 95–100%), and a false negative result at 0% (95% confidence interval = 0–5%). The results from detection of the Lubs syndrome and the 17q11.2 microduplication further confirm that MQF-PCR also presents a reliable method for the detection of human microduplication syndromes.

Discussion

In the past few years, dozens of clinically relevant chromosomal microdeletions and microduplications have been described in humans, often associated with mental deficiency, autism and/or physical malformations [1]. Since these small genomic arrangements are generally below the detection limit of optical microscopy, it is essential to use molecular diagnostic procedures to furnish an explanation for the observed symptoms and signs and to provide clinical and genetic prognoses for the patients and their families. In developed countries, pangenomic microarray-based molecular tests, particularly aCGH, have become the gold standard for such laboratory diagnosis [44]. However, these tests are very costly and depend on availability of expensive equipment that needs to be frequently upgraded. As a result of these high costs, patients in developing countries do not have access to the tests and are frequently left undiagnosed, with great prejudice for their families.

Although some microdeletion/microduplication syndromes have ill-defined phenotypes, many of them, indeed the most common ones, can be reliably diagnosed on clinical grounds. This propitiates laboratory confirmation to be made using simpler targeted molecular tests. In this article we describe the use of an inexpensive quantitative fluorescent PCR method for targeted identification of patients bearing microdeletion and microduplication syndromes that we proposed to call MQF-PCR (Microdeletion/Microduplication Quantitative Fluorescent PCR). The MQF-PCR method achieved 100% sensitivity and 100% specificity.
ficity in the detection of patients with the Williams-Beuren syndrome, Velocardiofacial syndrome, Lubs syndrome (MECP2 duplication) and the 17q11.2 microduplication involving the gene NF1. We believe that our method can be expanded to any syndrome originating from loss or gain of genomic material. We developed highly promising primer pairs for several other rarer syndromes where comprehensive validation is pending the collection of additional patients.

The MQF-PCR test is very rapid, allowing results to be reached in a just a few hours. Since the method uses a very cost-efficient fluorescent labeling utilizing a single universal fluorescent primer coupled with signal detection provided using equipment readily available in paternity and forensic laboratories in developing countries, the price of the necessary materials is low. In fact, it is possible to perform complete analyses at less than US$8.00 per sample, significantly less than a comparable targeted test using MLPA, which costs US$100.00 per sample in Brazil. Unlike Real-Time PCR, our method employs a single primer that allows robust internal control of amplification throughout the PCR reaction. Any deviations between amplification efficiency of the test and control amplicons are therefore tightly controlled and result in excellent reproducibility. Consequently, only one diagnostic primer pair was necessary to accurately identify affected individuals, which also contributes to reduced cost compared to Real-Time PCR and MLPA where multiple primer pairs are used in order to gain confidence in results. Our results were reliable and indeed we found no advantage of performing experiments in replicates. This probably was a consequence of normalization of our results with those of a DNA pool of one hundred normal individuals amplified and analyzed in parallel with the test sample. Furthermore, by the fact that it makes use of ideally matched internal controls, it delivers satisfactory results using a range of template DNA concentrations and is not limited to high quality DNA. The overall template quality does not seem to affect the performance of our method. Indeed, samples stored for 10 years at 4°C have provided satisfactory results. MQF-PCR has shown to be applicable to clinical material embedded in paraffin.

In summary, MQF-PCR has been developed as a rapid, reliable and cost-effective method for screening and detection of several human microdeletion and microduplication syndromes. Its ease
and low cost make it accessible to any clinical diagnostic laboratory. It is thus ideally suited for diagnostic use in developing countries, but has general applicability as well. However, its validation as a conclusive diagnostic procedure is still pending the collection of additional patients.

Supporting Information

Table S1 Summary of primers used in molecular diagnosis of Williams-Beuren and Velo-cardiofacial syndromes using polymorphic microsatellites and Real-Time PCR.

References

1. Weise A, Mrasek K, Klein E, Malatinho M, Llerena JC Jr, et al. (2012) Microdeletion and microduplication syndromes. J Histochim Cytochem 60: 346–358.
2. Gijsbers AC, Ruivenkamp CA (2011) Molecular karyotyping from microscope to SNP arrays. H Horm Res Pediatr 76: 206–213.
3. Crottwell PL, Hoyme HE (2012) Advances in whole-genome genetic testing from chromosomes to microarrays. Curr Probl Pediatr Adolesc Health Care 42: 47–71.
4. Schaal CP, Wisniewska J, Beaudet AL (2011) Copies number and SNP arrays in clinical diagnostics. Annu Rev Genomics Hum Genet 12: 25–51.
5. Carr IM, Diggle CP, Khan K, Inglehearn C, McKibbin M, et al. (2012) Rapid visualisation of microarray copy number data for the detection of structural variations linked to a disease phenotype. PLoS One 7: e43866.
6. Carr IM, Markham SA, Penna SDJ (2011) Estimating the degree of identity by descent in consanguineous couples. Hum Mutat 32: 1350–1358.
7. Shaffer LG, Beijam BA, Törchen B, Kirkpatrick S, Coppinger J, et al. (2007) The identification of microdeletion syndromes and other chromosome abnormalities: cytogenetic methods of the past, new technologies for the future. Am J Med Genet C Semin Med Genet 145C: 335–345.
8. Tonk V, Schneider NR, Delgado MR, Mao J, Schultz RA (1996) Identification and molecular characterization of a small chromosome 10q duplication [dubdup10(q24.2:q24.3] inherited from a mother mosaic for the abnormality. Am J Med Genet 61: 16–20.
9. Magenis RE, Maidlen CL, Smith L, Allen L, Sakai LY (1991) Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics 11: 346–351.
10. Weksberg R, Hughes S, Moldovan L, Bassett AS, Chow EW, et al. (2005) A method for accurate detection of genomic microdeletions using real-time quantitative PCR. BMC Genomics 6: 190.
11. Truong HT, Selayman-Kohal S, Baker KR, Girirajan S, Williams SR, et al. (2008) Diagnosing Smith-Magenis syndrome and duplication 17p11.2 syndrome by RALI gene copy number variation using quantitative real-time PCR. Genet Test Mol Biomarkers 12: 67–73.
12. Schouten JP, McElgunn CJ, Wajer R, Zijnenburg D, Diepvens F, et al. (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30: e57.
13. White SJ, Vink GR, Kriek M, Wuyts W, Schouten J, et al. (2004) Two-color quantitative PCR. BMC Genomics 6: 180.
14. Mutter GL, Pomponio RJ (1991) Molecular diagnosis of sex chromosome aneuploidy using quantitative PCR. BMC Genomics 6: 190.
15. Truong HT, Solaymani-Kohal S, Baker KR, Girirajan S, Williams SR, et al. (2008) Diagnosing Smith-Magenis syndrome and duplication 17p11.2 syndrome by quantitative PCR. BMC Genomics 6: 180.
16. Moles KJ, Gowans GC, Beversdorf D, Yu A, et al. (2012) NFI microduplications: identification of seven nonrelated individuals provides further characterization of the phenotype. Genet Med 14: 506–514.
17. Schuelke M (2000) An economic method for the fluorescent labeling of PCR fragments. Nat Biotechnol 18: 233–234.
18. Brownstein MJ, Carpton JD, Smith JR (1996) Modulation of non-templated nucleotide addition by Taq DNA polymerase: primer modifications that facilitate genotyping. Biotechniques 20: 1004–1006, 1008–1010.
19. Schouten JP, McElgunn CJ, Wajer R, Zijnenburg D, Diepvens F, et al. (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30: e57.
20. Laitinen J, Samarut J, Holtta E (1994) A nontoxic and versatile protein salting-out method for accurate detection of genomic microdeletions using real-time quantitative PCR. BMC Genomics 6: 190.
21. Urban ZC, Csiszár K, Fekete G, Boyd CD (1997) Short report on DNA marker and its use to confirm assignment of the gene to chromosome 7. Ann Hum Genet 57: 87–96.
22. Mari A, Amati F, Conti E, Bengala M, Novelli G, et al. (1990) A highly polymorphic CA/CT repeat (LIMK1GT) within the Williams syndrome critical region. Clin Genet 53: 226–227.
23. Gilbert-Dussardier B, Bonneau D, Gigalet N, Le Merrer M, Bonnet D, et al. (1995) A novel microsatellite DNA marker at locus D7S1870 detects hemizygosity in 75% of patients with Williams syndrome. Am J Hum Genet 56: 542–544.
24. Marineau C, Aubrey M, Julien JP, Rouleau GA (1992) Dinucleotide repeat polymorphism at the D22S263 locus. Nucleic Acids Res 20: 1430.
25. Morrow B, Goldberg R, Carbon C, Das Gupta R, Sirotkin H, et al. (1995) Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome. Am J Hum Genet 56: 1391–1403.
26. Rosenberg C, Knippenburg J, Bakker E, Viana-Morgante AM, Sloos W, et al. (2009) Array-CGH detection of microarrangements in mentally retarded individuals: clinical significance of imbalances present both in affected children and normal parents. J Med Genet 46: 180–186.
27. Carvalho CM, Zhang F, Lin P, Patel A, Sahoo T, et al. (2009) Complex rearrangements in patients with duplications of MECP2 can occur by fork stalling and template switching. Hum Mol Genet 18: 2188–2203.
28. Bauters M, Van Eeck H, Friez MJ, Boespflug-Tanguy O, Zener M, et al. (2008) Nonrecurrent MECP2 duplications mediated by genomic architecture-driven DNA breaks and break-induced replication repair. Genome Res 18: 847–858.
29. Weksberg R, Hughes S, Moldovan L, Bassett AS, Chow EW, et al. (2005) A method for accurate detection of genomic microdeletions using real-time quantitative PCR. BMC Genomics 6: 190.
30. Moles KJ, Gowans GC, Beversdorf D, Yu A, et al. (2012) NFI microduplications: identification of seven nonrelated individuals provides further characterization of the phenotype. Genet Med 14: 506–514.
31. Schuelke M (2000) An economic method for the fluorescent labeling of PCR fragments. Nat Biotechnol 18: 233–234.
32. Brownstein MJ, Carpton JD, Smith JR (1996) Modulation of non-templated nucleotide addition by Taq DNA polymerase: primer modifications that facilitate genotyping. Biotechniques 20: 1004–1006, 1008–1010.
33. Schouten JP, McElgunn CJ, Wajer R, Zijnenburg D, Diepvens F, et al. (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30: e57.
34. Lanzante JR (1996) Resistant, robust and nonparametric techniques for the fundamental evaluation tool in clinical medicine. Clin Chem 39: 561–577.
35. Metz CE (1978) Basic principles of ROC analysis. Semin Nucl Med 8: 283–298.
36. Metz CE (1978) Basic principles of ROC analysis. Semin Nucl Med 8: 283–298.
37. Ziegler IG (1978) Basic principles of ROC analysis. Semin Nucl Med 8: 283–298.
38. Ziegler IG (1978) Basic principles of ROC analysis. Semin Nucl Med 8: 283–298.
39. Ziegler IG (1978) Basic principles of ROC analysis. Semin Nucl Med 8: 283–298.
40. Ziegler IG (1978) Basic principles of ROC analysis. Semin Nucl Med 8: 283–298.
41. Merla G, Brunetti-Pierri N, Micale L, Fusco C (2010) Copy number variants at 4q21 in autistic individuals with ID. Nucleic Acids Res 38: 12358–12366.
42. Shaikh TH, Kurahashi H, Saitta SC, O’Hare AM, Hu P, et al. (2000) Detection of microdeletions in velo-cardio-facial syndrome using polymorphic microsatellites and Real-Time PCR.